- Short communication
- Open Access
Identification of amplified and highly expressed genes in amplicons of the T-cell line huT78 detected by cDNA microarray CGH
© Meléndez et al; licensee BioMed Central Ltd. 2005
- Received: 30 July 2004
- Accepted: 18 January 2005
- Published: 18 January 2005
Conventional Comparative Genomic Hybridization (CGH) has been widely used for detecting copy number alterations in cancer and for identifying regions containing candidate tumor responsible genes. Recently, several studies have shown the utility of cDNA microarray CGH for studing gene copy changes in various types of tumors. However, no such studies on T-cell lymphomas have been performed. To date T-cell lymphomas analyzed by the use of chromosome CGH have revealed only slight copy number alterations and not gene amplifications.
In the present study, we describe the characterization of three amplicons of the T-cell line huT78 located at 2q34-q37, 8q23-q24 and 20p, where new amplified and overexpressed genes are found. The use of a cDNA microarray containing 7.657 transcripts allowed the identification of certain genes, such as BCLX, PCNA, FKBP1A, IGFBP2 and cMYC, that are amplified, highly expressed, and also contained in the amplicons on 20p and 2q. The expresion of these genes was analyzed in 39 T-cell lymphomas and 3 other T-cell lines.
By the use of conventional CGH and CGH and expression cDNA microarrays we defined three amplicons in the T-cell line huT78 and identified several novel gene amplifications (BCLX, PCNA, FKBP1A, IGFBP2 and cMYC). We showed that overexpression of the amplified genes could be attributable to gene dosage. We speculate that deregulation of those genes could be important in the development of T-cell lymphomas and/or in the maintenance of T-cell lines.
- Comparative Genomic Hybridization
- Additional Data File
- Copy Number Gain
- huT78 Cell
- Gene Copy Number Gain
Gene amplification plays an important role in the progression and initiation of many solid tumors, as is the case of breast cancer where amplification of the genes ERBB2 (17q12), cMYC (8q24), and CCND1 (11q13) are found in 10–25% of breast tumors. Amplifications are revealed by Comparative Genomic Hybridization (CGH) in small chromosome areas (restricted to 2–10 Mb) where DNA copy number increases from more than 5 to 10-fold. Within these amplicons it is possible to identify critical amplified genes that are also overexpressed: this is the case for cMYC (8q24.12), ERBB2 (17q12-q21), MDM2 (12q14.3-q15) or BCL2 (18q21.3) [1–3]. Recently array-based CGH on cDNA microarrays has been used to investigate the genomic alterations with high resolution. Using this technique exhaustive analysis of the 17q12 and 17q23 amplicons in breast cancer has led to the identification of other genes that are also contained in the amplicons and whose overexpression could also be attributable to gene amplification [4–8]. Other recent studies in prostate cell lines  and in neuroblastoma tumors [10, 11] have also shown the utility of cDNA microarray CGH in defining amplicon boundaries and in analyzing the complexity of the amplicons. Tumor-related genes contained in amplicons are identified in these works due to the posibility of correlating gene expression to gene dosage data. To date, however, no amplifications have been described in primary tumors or cell lines derived from T-cell lymphomas [12, 13].
The cutaneous T-cell line huT78 was obtained from American Type Culture Collection (Rockville, MD) and cells were grown under recommended culture conditions. High molecular weight DNA was extracted and CGH was performed as described previously [12, 14].
In order to define regions of high-level amplification and to identify amplified and highly expressed genes contained in the amplicons, we performed cDNA microarray experiments on T-cell line huT78 to obtain expression and genomic profiles of the amplicons. We used the CNIO Oncochip (v1.1a) containing 7.657 different sequence-validated I.M.A.G.E cDNA clones (Research Genetics; Huntsville, AL) -some of them duplicated to reach a total of 11.718 spots- that represent known genes and expressed sequence tags (ESTs) related to the tumoral process, and tissue specific genes. A complete list can be found at http://bioinfo.cnio.es/data/oncochip/.
Genomic DNA hybridizations on microarrays were performed using DNA extracted from the T-cell line huT78 and from the blood of a control donor used as a reference. Genomic DNAs were Alu I and Rsa I digested, labeled with Cy5 (huT78) and Cy3 (control) using BioPrime labeling kit (Life Technologies, Inc., Gaithersburg, MD), and hybridized on microarrays at 50°C for 14–16 h, as previously described . Post-hybridization washes were performed and microarrays were scanned using a GenePix scanner (Axon Instruments, Foster City, CA). Fluorescence ratios Cy5/Cy3 were obtained and normalized by adjusting these ratios to a normalized factor so that the median of the ratios of all spots in the array equals 1. Only measurements with fluorescence intensities higher than two times the sum of the background averages' of both fluorochromes (Cy3 and Cy5) were considered reliable. Logarithms of the fluorescence ratios (log2 values) were calculated and used for the analysis. The CNIO Oncochip contains 7.657 different clones, of which 3.079 are replicated at least twice: thus, we removed and averaged the replicates by using an in-house developed preprocessing tool .
Expression data was also obtained from huT78 cells and from magnetically isolated T lymphocytes obtained from the pooled peripheral blood of 5 anonymous donors that were used as a control. T lymphocytes were isolated by using either magnetic microbeads conjugated to monoclonal mouse anti-human CD3 antibodies purchased from Miltenyi Biotec Inc. (Auburn, CA), or magnetic depletion of non-T-cells with a cocktail of antibodies using the Pan T-cell Isolation Kit (Miltenyi Biotec Inc.). Total RNAs were extracted with Tri Reagent (Molecular Research Center, Cincinnati, OH) following the manufacturer's instructions and amplified using a T7-based method, as previously described [17, 18]. Briefly, 5 μgr of total RNA were used to produce double-stranded cDNA (Superscript Choice System, Life technologies Inc.) and amplification of mRNAs was performed using the Megascript T7 in vitro transcription kit (Ambion, Austin, TX) following manufacturer's recommendations. A pool of aRNAs obtained from the Universal Human RNA (Stratagene, La Jolla, CA) was used as a standard reference in all hybridizations. Test or reference amplified RNAs (aRNAs) were labeled with fluorescent Cy5 and Cy3, respectively, as reported  and hybridized on microarrays at 42°C for 15 hours. Fluorescence ratios (Cy5/Cy3) were normalized and filtered for genomic data. The Cy5/Cy3 ratios obtained in the cell line hybridization were then compared to those obtained in control T lymphocytes hybridization.
In order to analyze if the candidate genes contained in the amplicons are altered in primary tumors and other cell lines, we analyzed expression data obtained in a previous study  using tumor samples from 39 primary T-cell lymphomas and 3 cell lines (Jurkat, Molt 16 and Karpas 45). Sample description and clinical details are specified in the work from Martinez-Delgado et al. . All the tumors were diagnosed according to the World Health Organization classification criteria, and all individuals had given official consent.
Expression and copy number profiling
Genes highly gained and overexpressed in huT78 cell line.
inhibitor of DNA binding 3, dominant negative helix-loop-helix protein
X-ray repair complementing defective repair in Chinese hamster cells 5
insulin-like growth factor binding protein 2
proteasome subunit, beta type, 3
von Hippel-Lindau syndrome
cadherin, EGF LAG seven-pass G-type receptor 3
Arg/Abl-interacting protein ArgBP2
MCM3 minichromosome maintenance deficient 3
general transcription factor II, i
P450 (cytochrome) oxidoreductase
hypoxia-inducible protein 2
N-acetylneuraminic acid phosphate synthase; sialic acid synthase
prostate cancer overexpressed gene 1
thyroid hormone responsive
CD63 antigen (melanoma 1 antigen)
suppressor of Ty 6 homolog (S. cerevisiae)
interleukin enhancer binding factor 1
serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2
ubiquinol-cytochrome c reductase subunit
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7
cytochrome P450, subfamily IIA, polypeptide 7
FK506 binding protein 1A
BCL2-like 1, Bcl-X
GNAS complex locus
Amplicons on chromosomes 20, 2 and 8
Genes in amplicons of chromosome 2, 8 and 20.
Genes in amplicon of Chromosome 20
Genes in amplicon of chromosome 2
Genes in amplicon of chromosome 8
Using CGH, amplicon in chromosome 2 is narrower than amplicon in chromosome 20 (Figure 1). In fact it seems to be restricted to a few genes if genomic data are examined (Table 2). Only two areas, one around 220 and the other around 227 Mb, present the highest genomic values (shadowed in table 2), with 4 genes overexpressed: XRCC5 (2q35) and IGFBP2 (2q33-24) around 220 Mb, TUBA1 (tubulin, alpha 1) around 227 Mb and PSMD3 mapped by FISH at 2q35. Amongst these, IGFBP2 is the most highly overexpressed (Table 2).
Amplicon in chromosome 8 is located at 8q23-q24, where the gene cMYC is located. This gene was found as amplified in other tumors and in this study we show that it is also amplified in the cell line huT78. cMYC is not however highly expressed in this cell line (Table 2). Chromosome 8 amplicon affects a wide region, from 132 to 146 Mb (shadowed in table 2), but only one gene located within this area is overexpressed, LY6E (lymphocyte antigen 6 complex, locus E). This gene is upregulated by all-trans-retinoic acid (ATRA), a differentiation inducer capable of causing clinical remission in about 90% of patients with acute promyelocytic leukemia. Other genes located in the amplicon that have not been analyzed in this study could also be important.
Analyses of the amplicon candidate genes in primary T-cell lymphomas and cell lines
Expression of the relevant genes found in the amplicons that were gained in this T-cell line were examined in a series of 39 primary T-cell lymphomas and 3 T-cell lines (Jurkat, Molt 16 and Karpas 45) . Three genes located in 20q amplicon were overexpressed in the majority of primary tumors and stablish cell lines. FKBP1A and PCNA were overexpressed in 89,7 and 71,8% respectively (35 and 28 out of 39) of the primary tumors and in all the three cell lines analyzed. In addition, BCLX was overexpressed in 64,1% (25/39) of the primary tumors and in Jurkat cell line. Regarding genes in amplicons of chromosome 2 and 8, IGFBP2 was only overexpressed in 15,4% (6/39) of the tumors and cMYC is not highly expressed in any of them. However, both genes were overexpressed in the three cell lines.
Conventional chromosome CGH of the T-cell line huT78 showed genomic patterns of copy number changes affecting most of the chromosomes. Three highly amplified regions were detected using this technique. Nevertheless, resolution of chromosome CGH is no less than 2 Mb for copy number gains and is a function of both amplicon size and copy number gains .
In order to precisely define regions of high-level amplification and to identify amplified and highly expressed genes contained in the amplicons of the T-cell line huT78, we performed cDNA microarray CGH and expression profiling of the cell line. For this purpose, we used the CNIO Oncochip containing 7.657 different sequence-validated cDNA clones that represent known genes and expressed sequence tags (ESTs) related to the tumoral process, and tissue specific genes.
Recently, several studies have shown the utility of cDNA microarray CGH for studing gene copy changes in various types of tumors, and the usefulness of defining amplicon boundaries at high resolution (gene level) to assist in locating and identifying candidate oncogenes [4–11]. However, to date, no such studies on T-cell lymphomas have been performed. In the present study, we determined the precise locations of gene amplifications in the T-cell line huT78 by the use of array-based CGH on cDNA microarrays. We observed that, although chromosome CGH detected amplicons of different size (as for example the amplicons on chromosomes 20 and 2), the structure of those amplicons is more complex when it is analyzed at high resolution. Amplicon in chromosome 20 extends along all p arm when detected by use of chromosome CGH. Instead, several peaks of amplification, different in magnitude, appear at 3, 5–6, 10 and 29–30 Mbs when analyzed at gene-by-gene level. Amplicon in chromosome 2, although showing a narrower shape by chromosome CGH than that of chromosome 20, also presented a complex structure at high resolution, with two peaks of amplification around 220 and 227 Mbs.
By analyzing mRNA levels in parallel, we observed that not all genes that are amplified are also overexpressed. Thus, by analyzing the expression of the genes contained in the amplicons, we selected several genes whose expression seemed to respond to gene copy number gains. We showed that only a few of the genes contained in the amplicon are highly gained and also overexpressed. In this way we could select the candidate genes to study further that could be involved in the tumorogenesis of the T-cell lymphomas.
As stated before , however, the elevated expression of an amplified gene cannot alone be considered strong independent evidence of a candidate oncogene's role in tumorigenesis. Thus, we examined the expression of the selected candidate genes in a series of 39 primary T-cell lymphomas and 3 T-cell lines (Jurkat, Molt 16 and Karpas 45) . Three genes located in 20q amplicon were overexpressed in the majority of primary tumors and stablish cell lines. FKBP1A, PCNA and BCLX were overexpressed in 90–65% of the primary tumors. FKBP1A is a receptor for rapamicin as well as for FK506, a powerful immunosuppressant in T-cells, and PCNA is involved in the control of eukaryotic DNA replication and may have a role in DNA repair synthesis. BCLX is involved in both positive and negative regulation of programmed cell death. Thus, these three genes, could be significant in the development of T-cell lymphomas.
When the candidate genes located in amplicons of chromosome 2 and 8 were examined, we observed that IGFBP2 was only overexpressed in a low proportion of the primary tumors (15%) and cMYC is not highly expressed in any of them. Curiously, both genes were overexpressed in the three cell lines suggesting that they could be of relevance in the maintenance of the cell lines.
We have identified 3 amplicons by CGH in the T-cell line huT78. By cDNA microarray CGH. We have narrowed down the regions and selected some amplified and overexpressed genes: BCLX, PCNA and FKBP1A. These genes are also overexpressed in 65–90% of a set of 39 T-cell lymphomas and 3 cell lines, while IGFBP2 and cMYC are only overexpressed in T-cell lines. Our data suggest a different role of these genes in such processes. New studies with more clones covering these amplicons can help us to better identify relevant genes in T-cell lymphomas.
We thank Amanda Wren for her technical assistance. This work was partially supported by the Comunidad Autonoma de Madrid grants CAM 08.6/0005.1/2001 and CAM 08.1/0020.1/00. RD-U was partially supported by a Ramón y Cajal programme from the Spanish Ministry of Science (MCyT) and by Project TIC2003-09331-C02-02 of the Spanish MCyT.MC is a fellow of the Colegio de Farmaceuticos.
- Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O, Szymanska J, Larramendy ML, Tapper J, Pere H, El-Rifai W, Hemmer S, Wasenius VM, Vidgren V, Zhu Y: DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol. 1998, 152: 1107-1123.PubMed CentralPubMedGoogle Scholar
- Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, Lushnikova T, Monni O, Pere H, Tapper J, Tarkkanen M, Varis A, Wasenius VM, Wolf M, Zhu Y: DNA copy number losses in human neoplasms. Am J Pathol. 1999, 155: 683-694.PubMed CentralView ArticlePubMedGoogle Scholar
- Knuutila S, Autio K, Aalto Y: Online access to CGH data of DNA sequence copy number changes. Am J Pathol. 2000, 157: 689-PubMed CentralView ArticlePubMedGoogle Scholar
- Kauraniemi P, Barlund M, Monni O, Kallioniemi A: New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res. 2001, 61: 8235-8240.PubMedGoogle Scholar
- Monni O, Barlund M, Mousses S, Kononen J, Sauter G, Heiskanen M, Paavola P, Avela K, Chen Y, Bittner ML, Kallioniemi A: Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci U S A. 2001, 98: 5711-5716. 10.1073/pnas.091582298PubMed CentralView ArticlePubMedGoogle Scholar
- Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozenblum E, Ringner M, Sauter G, Monni O, Elkahloun A, Kallioniemi OP, Kallioniemi A: Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res. 2002, 62: 6240-6245.PubMedGoogle Scholar
- Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Borresen-Dale AL, Brown PO: Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A. 2002, 99: 12963-12968. 10.1073/pnas.162471999PubMed CentralView ArticlePubMedGoogle Scholar
- Pollack JR, Iyer VR: Characterizing the physical genome. Nat Genet. 2002, 32 Suppl: 515-521. 10.1038/ng1035View ArticlePubMedGoogle Scholar
- Wolf M, Mousses S, Hautaniemi S, Karhu R, Huusko P, Allinen M, Elkahloun A, Monni O, Chen Y, Kallioniemi A, Kallioniemi OP: High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression. Neoplasia. 2004, 6: 240-247.PubMed CentralView ArticlePubMedGoogle Scholar
- Beheshti B, Braude I, Marrano P, Thorner P, Zielenska M, Squire JA: Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization. Neoplasia. 2003, 5: 53-62.PubMed CentralView ArticlePubMedGoogle Scholar
- Chen Q-R, Bilke S, Wei JS, Whiteford CC, Cenacchi N, Krasnoselsky AL, Greer BT, Son C-G, Westermann F, Berthold F, Schwab M, Catchpoole D, Khan J: cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma. BMC Genomics. 2004, 5: 70- 10.1186/1471-2164-5-70PubMed CentralView ArticlePubMedGoogle Scholar
- Renedo M, Martinez-Delgado B, Arranz E, Garcia M, Urioste M, Martinez-Ramirez A, Rivas C, Cigudosa JC, Benitez J: Chromosomal changes pattern and gene amplification in T-cell non-Hodgkin's lymphomas. Leukemia. 2001, 15: 1627-1632. 10.1038/sj.leu.2402248View ArticlePubMedGoogle Scholar
- Struski S, Doco-Fenzy M, Cornillet-Lefebvre P: Compilation of published comparative genomic hybridization studies. Cancer Genet Cytogenet. 2002, 135: 63-90. 10.1016/S0165-4608(01)00624-0View ArticlePubMedGoogle Scholar
- Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, Pinkel D: Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer. 1994, 10: 231-243.View ArticlePubMedGoogle Scholar
- Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, Jeffrey SS, Botstein D, Brown PO: Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet. 1999, 23: 41-46. 10.1038/14385View ArticlePubMedGoogle Scholar
- Herrero J, Díaz-Uriarte R, Dopazo J: Gene expression data preprocessing. Bioinformatics. 2003, 19: 655-656. 10.1093/bioinformatics/btg040View ArticlePubMedGoogle Scholar
- Eberwine J: Amplification of mRNA populations using aRNA generated from immobilized oligo(dT)-T7 primed cDNA. Biotechniques. 1996, 20: 584-591.PubMedGoogle Scholar
- Tracey L, Villuendas R, Ortiz P, Dopazo A, Spiteri I, Lombardia L, Rodriguez-Peralto JL, Fernandez-Herrera J, Hernandez A, Fraga J, Dominguez O, Herrero J, Alonso MA, Dopazo J, Piris MA: Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. Am J Pathol. 2002, 161: 1825-1837.PubMed CentralView ArticlePubMedGoogle Scholar
- Martinez Delgado B, Melendez B, Cuadros M, Alvarez J, Castrillo JM, Mollejo M, Bellas C, Lombardía L, Al-Shahrour F, Dominguez O, Cascon A, Robledo M, Rivas C, Benitez J: Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res. 2004, 10: 4971-4982.View ArticlePubMedGoogle Scholar
- Beheshti B, Park PC, Braude I, Squire JA: Microarray CGH. Methods Mol Biol. 2002, 204: 191-207.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.